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We have evaluated two commercially available kits (AMPLICOR MONITOR [Roche] and NASBA HIV-1 QT
or NucliSens HIV-1 QT [Organon Teknika]) and two noncommercial methods for the accurate quantitation of
human immunodeficiency virus type 1 (HIV-1) RNA in seminal plasma. The same panels of coded specimens
were tested on four separate occasions. Laboratories using the commercial assays employed silica beads to
isolate HIV-1 RNA, which removed inhibitory factors sometimes found in seminal plasma. Sensitivities and
specificities, respectively, for each assay were as follows: AMPLICOR MONITOR, 100 and 73%; NASBA HIV-1
QT, 84 and 100%; NucliSens HIV-1 QT, 99 and 98%; and noncommercial assays, 91 and 73%. When results
from the laboratory that was inexperienced with the silica bead extraction method were excluded from the
analysis, specificity for the Roche assay increased to 100%. The commercial assays demonstrated highly
reproducible results, with intra-assay standard deviations (measured in log10 RNA copies/milliliter of seminal
plasma) ranging from 0.11 to 0.32; those of the noncommercial assays ranged from 0.12 to 0.75. Differences in
mean estimated HIV-1 RNA concentrations were <0.67 log10 and were greater at low viral loads. Suspension
matrices that used blood plasma or seminal plasma did not make a difference in recovery of HIV-1 RNA, which
suggested that blood plasma specimens can be used as external controls for seminal plasma assays. More
variation in the HIV-1 RNA viral loads was observed in the seminal plasma values than in the blood plasma
values when paired specimens from HIV-1-infected men were tested. Quantitation of HIV-1 RNA in seminal
plasma can be reliably accomplished using two commercially available assays, and may be incorporated into
the evaluations of HIV-1 seropositive men enrolled in clinical studies.
Sexual transmission of human immunodeficiency virus type
1 (HIV-1) is postulated to occur through direct exposure of the
oral, vaginal, urethral, or rectal mucosal surfaces to genital
secretions (semen and cervical vaginal secretions) from a sex-
ual partner. In 1996 the Centers for Disease Control and Pre-
vention indicated that sexual transmission of HIV-1 was the
primary route of HIV-1 infection in the United States in per-
sons aged 25 to 44 years (3). If blood and semen HIV-1 con-
centrations are predictive of the probability of HIV-1 trans-
mission, then strategies to decrease the viral load below a
critical level in both these compartments may ultimately re-
duce the rate of transmission.
Recovery of infectious HIV-1 from seminal cells has been
highly variable (9 to 55%) and also inconsistent within an
individual over time in longitudinal studies (11). Seminal
plasma infrequently yields infectious virus (10, 18). Early ef-
forts to quantitate virus in seminal plasma used noncommer-
cial reverse transcription (RT)-PCR amplification techniques
(1, 9, 12, 14, 17) and employed external standards as the
method of quantification. When RT-PCR kits that used inter-
nal quantitation standards became commercially available, it
became clear that seminal plasma often contained inhibitors of
the RT-PCR. This inhibition could be removed by using silica
beads to isolate the viral RNA (5, 6, 8).
Multicenter clinical drug trials are now actively studying
the effects of different antiretroviral drug regimens on the
viral load in blood and the genital tract, including the eval-
uation of viral load in genital secretions in relation to HIV-1
transmission. We have evaluated the various methods in the
processing, isolation, and quantitation of HIV-1 RNA in
seminal plasma and developed a standardized method to
facilitate the comparison of data generated by studies in the
field. This manuscript describes the technical performance
characteristics of both commercial and noncommercial
HIV-1 RNA assays which have been used to measure sem-
inal plasma HIV-1 RNA and compares blood plasma with
seminal plasma as a dilution matrix for the preparation of
controls and proficiency panels.
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MATERIALS AND METHODS
Quantitative HIV RNA assays. Two commercially available assays were com-
pared: the Roche AMPLICOR MONITOR assay and the Organon Teknika
NASBA HIV-1 QT assay or NucliSens HIV-1 QT assay (hereafter in this work
the Organon Teknika assays are referred to as NASBA and NucliSens, respec-
tively). These assays have been described elsewhere (7, 13, 16). Additionally, two
laboratories employed noncommercial assays. The Roche MONITOR assay was
used according to the manufacturer’s instructions except for HIV-1 RNA isola-
tion. Instead, viral RNA was isolated using the silica bead procedure of Boom et
al. (2). Previous experiments had demonstrated that factors in some seminal
plasma specimens inhibited RT-PCR amplification and that these inhibitors were
removed by silica bead extraction (5, 6, 8). The limit of detection of the
MONITOR assay is 400 copies/ml.
The Organon Teknika NASBA assay was used for the first panel according to
the manufacturer’s instructions, with the exception that kit calibrators were
diluted 10-fold to increase assay sensitivity. Over the course of the study period,
Organon Teknika introduced a more-sensitive RNA assay, NucliSens, which was
used for the remaining test panels without modification. The silica bead extrac-
tion method of viral RNA is an inherent part of the Organon Teknika assay. The
limit of detection is 1,000 copies/ml for the NASBA assay and 400 copies/ml for
the NucliSens assay.
Two sites used similar assays that were developed in their own laboratories.
Both methods pelleted HIV-1 virions from seminal plasma using centrifugation
at $14,000 3 g for 60 min at 4°C. Pellets were then resuspended in Tri Reagent
(4), and viral RNA was extracted with chloroform and isopropanol. The HIV-1
RNA was then subjected to RT-PCR using published methods (14, 15). Briefly,
HIV RNA was reverse transcribed to cDNA that was then amplified using Taq
polymerase and either SK38 and SK39 primers over 35 cycles (14) or the fol-
lowing primers: Sense, CAATGAGGAAGCTGCAGAATGGGATAG, and
Anti-sense, CATCCATCCTATTTGTTCCTGAAGG. Amplicons were detected
by hybridization with a 32P-labeled SK19 probe or ATGAGAGAACCAAGGG
GAAGTGACATAGCA (15). The RNA copy numbers were estimated by com-
parison to a standard curve.
Participating laboratories. Eight laboratories (coded A to H) participated in
the evaluation at one or more times. Technologists performing the respective
assays had previous experience in the performance of the nucleic acid amplifi-
cation assays using blood plasma. However, two laboratories (B and E) did not
have previous experience with the Boom silica bead method of viral RNA
extraction (2) and four laboratories (B, D, E, and F) did not have previous
experience with viral RNA measurements from seminal plasma specimens. In the
first round of testing, two laboratories (one experienced in testing seminal
plasma [A] and one inexperienced [B]) used the Roche MONITOR assay.
Similarly, an experienced laboratory (C) and an inexperienced laboratory (D)
used the NASBA assay. Two laboratories used their own noncommercial assay
(laboratories G and H). For the second and third rounds of testing, two different
laboratories (E and F), neither of which had experience with seminal plasma viral
RNA determination, assayed the panels using the Organon Teknika assay, re-
placing laboratory D. Overall, six laboratories tested seminal plasma panel 1
(SP01), seven tested panel 2a (SP2a), five tested panel 2b (SP02b), and five tested
panel 3 (SP03).
Composition of test panels. The Virology Quality Assurance Laboratory of the
National Institutes of Health provided three separate blinded panels of speci-
mens for testing (SP01, SP02, and SP03) to each of the participating laboratories.
Panels SP01 and SP02 consisted of pooled HIV-negative seminal plasma diluted
1:1 in either Hanks’ balanced salt solution (SP01) or phosphate-buffered saline
(SP02) into which a known quantity of HIV-1 was added (henceforth referred to
as the nominal concentration of HIV-1 RNA). Panel SP01 consisted of six
specimens each at nominal concentrations of 103 and 104 HIV RNA copies/ml,
five specimens each at 105 and 106 copies/ml, and two negative specimens. Panel
SP02 consisted of four negative specimens and five replicates at each of the
following nominal concentrations: 103, 104, 105, and 106 HIV RNA copies/ml.
The viral stock used was a highly characterized subtype B HIV-1 obtained from
pooled culture supernatants from three HIV-1-seropositive donors (19). Virol-
ogy Quality Assurance Laboratory standards used in each panel were prepared
by diluting the same viral stock into HIV-1-seronegative blood plasma. Panel
SP02 was tested on two separate occasions approximately 4 months apart, des-
ignated SP2a and SP2b. Panel SP03 consisted of triplicate aliquots of paired
blood plasma and cell-free seminal plasma from one HIV-1-seronegative and five
HIV-1-seropositive donors. Specimens were shipped frozen via overnight express
to each of the participating laboratories.
Statistical methods. Estimates of HIV-1 RNA concentration were first trans-
formed to the log10 scale. The intra-assay standard deviation (SD) of log-trans-
formed estimates from each panel in each laboratory was estimated from the
mean square error for a one-way analysis of variance, with the nominal concen-
tration as the predictor variable. Estimates that were below the limit of detection
were set at the limit for each kit. This negatively biased the SDs, but the bias was
confined to a few laboratories and was small, given the small number of values
below the limit of detection. Estimates were compared among laboratories using
regressions of log10 estimated HIV-1 RNA concentration on log10 nominal
HIV-1 RNA concentration. Both slopes and intercepts were allowed to vary
among laboratories in the initial model for each panel. If no differences among
slopes were detected on a panel, then a model with parallel regression lines was
assumed. Under this model, differences among laboratories did not vary with
nominal concentration and the differences were estimated from the intercepts for
the regressions. However, if slopes did differ, then the differences in estimated
RNA concentration among laboratories varied with RNA concentration. When
this occurred, the regression lines were compared graphically to determine if the
differences increased or decreased with concentration, and to estimate the mag-
nitude of interlaboratory variation. A similar regression approach was used to
compare data between rounds of testing on panel SP02, which used different
nonplasma dilution matrices, within laboratories and to compare estimates from
spiked seminal plasma and blood plasma for this panel.
RESULTS
Sensitivity and specificity of assays used for the quantita-
tion of HIV-1 RNA from seminal plasma. Tables 1 and 2
summarize the performance for each assay and participating
laboratory for the first two panels. Six laboratories (A, B, C, D,
TABLE 1. Performance characteristics for HIV-1 RNA quantification for the coded seminal plasma samples of panel SP01




A Roche 0 0 0.16 0.91 0.674 0.98
B Roche 3 0 0.15 0.75 1.581 0.96
C NASBA 0 4 0.20 0.94 0.399 0.96
D NASBA 0 3 0.14 0.86 0.790 0.98
G Noncommercial 0 0 0.12 0.89 2.146 0.98
H Noncommercial 0 6 0.75 0.65 1.503 0.36
TABLE 2. Performance characteristics for HIV-1 RNA quantification for the coded seminal plasma samples of panel SP02a




A Roche 0, 0 0, 0 0.11, 0.16 0.92, 0.96 0.30, 0.17 0.99, 0.98
B Roche 5, 0 0, 0 0.19, 0.14 0.73, 0.94 1.47, 0.31 0.93, 0.99
C NucliSens 0, 0 0, 0 0.14, 0.14 0.93, 1.03 0.31, 20.15 0.98, 0.99
E NucliSens 0, 0 0, 0 0.21, 0.17 0.98, 1.01 0.14, 20.10 0.97, 0.98
F NucliSens 0, 0 2, 0 0.29, 0.18 1.00, 0.94 20.07, 0.41 0.95, 0.98
G Noncommercial 3 0 0.61 0.59 2.87 0.59
a Panel SP02 was tested twice in five of the laboratories and once in laboratory G.
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G, and H) participated in the first round of testing (SP01)
(Table 1). One laboratory, inexperienced in the Boom RNA
extraction method and using a commercial kit, reported three
false-positive results (the two negative seminal plasma speci-
mens and the negative control), all of which had high estimates
of viral RNA (6,000 to 11,000 copies/ml). The two laboratories
that used the NASBA assay reported false negatives from
samples at 103 viral RNA copies/ml. Five of the six false neg-
atives from laboratory H occurred at 103 viral RNA copies/ml,
and one occurred at 104 viral RNA copies/ml.
Seven laboratories participated in the analysis of panel
SP02a (Table 2). One laboratory which was experienced in
seminal plasma testing encountered problems with a noncom-
mercial assay, and these data were excluded from the analysis.
Another laboratory experienced in seminal plasma testing, us-
ing a noncommercial assay, reported three false-positive re-
sults, all of which had very high estimates of viral RNA con-
centration (116,000 to 177,000 copies/ml). An additional
previously inexperienced laboratory, using the Roche assay,
reported five false positives (the four negative seminal plasma
specimens and the negative control), with estimates of viral
RNA concentration ranging from 2,874 to 7,267 copies/ml.
One inexperienced laboratory using the NucliSens assay could
not correctly identify two of the samples with 103 viral RNA
copies/ml (false negatives). No false positives or false negatives
were observed when five laboratories repeated testing of this
panel 4 to 5 months later (SP02b) (Table 2).
Panel SP03 consisted of paired seminal plasma and blood
plasma from five HIV-infected men and one uninfected man.
One false positive was reported for a semen specimen with a
calculated viral load of 200 HIV-1 RNA copies/ml (data not
shown). Combining data from all of the panels, the overall
sensitivities of the assays for detecting HIV-1 RNA in seminal
plasma were as follows: AMPLICOR, 100%; NASBA, 84%;
NucliSens, 99%; and noncommercial assays, 91%. Overall as-
say specificities for HIV-1 RNA were as follows: MONITOR,
73%; NASBA, 100%; NucliSens, 98%; and noncommercial
assays, 73%. If the laboratory inexperienced in the Boom ex-
traction procedure was excluded from the analysis, the speci-
ficity for the Roche assay increased to 100%.
Intra-assay variation. Standard deviations for log-trans-
formed estimates from seminal plasma varied widely among
panels and assays (Tables 1 and 2 and data not shown for
SP03) (range of log10 SDs: 0.11 to 0.75 viral RNA copies/ml).
The Roche MONITOR assay was the most consistent, with all
log10 SDs being #0.19 viral RNA copies/ml. Most of the log10
SDs for the NASBA and NucliSens assays were ,0.20 viral
RNA copies/ml, but values of 0.29 and 0.32 were also obtained.
The highest SDs were obtained from noncommercial assays
(range of log10 SDs, 0.12 to 0.75 viral RNA copies/ml).
In general, laboratories that used commercial kits obtained
similar estimated values for the specimens, which correlated
well with the nominal HIV-1 RNA concentrations for each
sample. This is shown by the slopes and intercepts for the
calculated regression lines (Tables 1 and 2). Slopes determined
by the laboratories that used the commercial assays ranged
from 0.73 to 1.03, with 11 of the 14 calculated slopes between
0.91 and 1.03. Intercepts derived from the data from these
same laboratories were also comparable, ranging from 20.15
to 1.59, with 12 of the 14 values between 20.15 and 0.79. In
contrast, laboratories which used noncommercial assays had
more shallow slopes (0.59 to 0.89) and higher intercepts (1.50
to 2.87), indicating that HIV-1 RNA estimates from these
laboratories would tend to be higher than the estimates ob-
tained in the five laboratories that used the commercially avail-
able kits. In addition, data from the laboratories that used
commercial kits were very precise (r2 $ 0.93), compared with
data from the other two laboratories (r2, 0.36 to 0.98).
Intralaboratory variation. The consistency of performance
within each of five of the laboratories that used commercial
assay kits was assessed by comparing estimates from the two
rounds of testing of panel SP02 that occurred 4 to 5 months
apart for both seminal and blood plasma (Table 2). Despite the
use of different kit lots between runs within laboratories and
the different suspension matrices, the results were highly re-
producible (Fig. 1 [panels for laboratories A, B, C, E, and F]).
Intra-assay variation was greater for samples with 103 HIV-1
RNA copies/ml than those with higher concentrations, espe-
cially in laboratories that used the NucliSens assay (Fig. 1
[panels for laboratories C, E, and F]). Overall there was re-
markable consistency in the results observed within laborato-
ries as well as between laboratories (Fig. [bottom right panel]).
Effect of type of body fluid matrix on the measurement of
HIV-1 RNA. We compared estimates of numbers of HIV-1
RNA copies per milliliter obtained from the spiked seminal
plasma samples and the spiked blood plasma controls to de-
termine if differences in composition of the suspension matrix
affected estimates of HIV-1 RNA concentration (panel SP02).
Neither the slopes nor the intercepts differed significantly be-
tween spiked seminal plasma samples and spiked blood plasma
controls in four of the five laboratories that used the commer-
cial assays (laboratories A, C, E, and F). The fitted regression
lines for the semen samples and plasma standards were essen-
tially superimposable, indicating that the estimates from the
two were almost identical. The eight regression lines derived
from laboratories A, C, E, and F were also extremely precise
(r2 . 0.95). RNA recovery from the blood plasma samples was
poor in laboratory B, resulting in a flatter slope and higher
intercept than those obtained from seminal plasma. However,
the great similarity of the paired regression lines in four of the
laboratories indicates that the suspension matrix did not make
a difference at least when the Boom RNA isolation method
was used.
Variation within specimen type. In panel SP03 paired blood
plasma and seminal plasma from HIV-1-seropositive donors
were evaluated using the two commercial assays. Results were
consistent between assays and among laboratories (Fig. 2).
Slightly more variation in copy number (average 0.05 log10 SD)
was observed when replicates of seminal plasma (Fig. 2B) were
tested than was observed with blood plasma (Fig. 2A). The
median SD (measured in log10 viral RNA copies/milliliter) for
blood plasma was 0.08 for the MONITOR assay and 0.06 for
the NucliSens assay. In contrast, the median SD for seminal
plasma was 0.12 for the MONITOR assay and 0.10 for the
NucliSens assay. None of these differences were statistically
significant.
DISCUSSION
HIV-1 RNA quantitation assays were originally developed
to assess viral RNA levels in blood plasma. Some of these
assays have also been used, sometimes with modification, to
measure viral load in seminal plasma. We evaluated several of
the previously published methods for quantifying HIV-1 RNA
from seminal plasma (5, 6, 14, 15) and found remarkable con-
sistency in HIV-1 RNA quantification in seminal plasma
among laboratories, even for those laboratories that had little
prior experience working with semen.
Our data indicate that the commercial assays provide more
sensitive and consistent results when used to assess viral load in
the seminal plasma than do noncommercial assays. These ob-
servations may be a consequence of the internal standards used
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by both of the commercial assay kits, which can signal the
presence of a problem with inhibition of viral nucleic acid
amplification. In addition, reagents for commercial kits are
prepared in large, well-characterized lots. All laboratories in
this study that used a commercial HIV-1 RNA assay kit also
used the silica procedure for viral RNA extraction, while those
laboratories that used noncommercial assays did not. Previous
studies have indicated that seminal plasma frequently contains
inhibitors of RT-PCR and that the silica bead isolation extrac-
tion procedure (2) can remove these inhibitors (5, 6, 8).
Although all of the laboratories which participated in these
evaluations were very experienced in performing HIV RNA
assays, laboratories B and E had never used the silica bead
RNA isolation procedure and laboratories B, D, E, and F had
never worked with seminal plasma. In particular, laboratories
A and B prepared their own silica beads and reagents, while
FIG. 1. Results obtained from repeated testing of SP02 in five laboratories that used the commercial HIV-1 RNA assay. (A to E) Scatter plots of log10 RNA
copies/milliliter from repeated testing of panel SP02. Circles represent SP02a results, and triangles represent SP02b results. The panel in the lower right corner shows
regression lines generated from all five laboratories from both rounds of testing.
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laboratories C, D, E, and F used commercially available re-
agents which were part of the Organon Teknika HIV RNA
kits. Laboratory B experienced the most problems, obtaining
several false positives in the first two panels tested. By the third
round of testing (panel SP02b), more-consistent results were
obtained. These results demonstrate that inexperience in just
one step in an assay can affect laboratory performance and also
indicate the value of quality assurance program evaluations.
Laboratories initiating studies that require silica bead extrac-
tion techniques might be advised to use the commercially avail-
able reagents.
There appeared to be no effect of the suspension matrix on
the ability to estimate HIV-1 RNA levels when the Boom silica
RNA extraction method and a commercial HIV-1 RNA quan-
tification kit were used. This is an important practical consid-
eration, as it suggests that the controls that were provided by
the manufacturer with each assay kit can be reliably used in
assays in which seminal plasma is the test specimen. We did
observe somewhat more variation when replicates of seminal
plasma were tested than when blood plasma was assayed (Fig.
2). The reasons for this are unclear but may be related to the
intrinsic complex biological nature of seminal plasma and the
fact that it is composed of fluids from several reproductive
compartments. Part of the increased variation observed among
the seminal plasma samples may also be due to the generally
lower copy numbers found in the seminal plasma compared to
blood plasma.
In summary, the NucliSens and AMPLICOR MONITOR
kits were found to quantify HIV-1 RNA in seminal plasma
reliably and comparably after isolation of viral RNA using the
silica bead procedure of Boom (2). This suggests that data
derived from one of the commercial assays could be easily
compared with data from the other, as might occur in different
clinical trials or natural history studies, and that data sets could
perhaps be pooled to achieve larger numbers and possibly
more statistical power for analysis purposes. The accurate and
reliable quantification of HIV-1 viral load in the seminal
plasma by these methods is fundamental to the evaluation of
therapeutic drug and vaccine candidates aimed at the reduc-
tion of viral load in the semen and the subsequent reduction in
HIV-1 transmission.
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